| P/E (FY) | 21.2 | Sales (TTM) | €874.8M |
| Earnings (TTM) | €80.6M | ROE | 16.69% |
| Net Margin | 9.21% | ROIC | 14.59% |
| Debt / Equity | 0.68 | TD / EBITDA | 1.99 |
| EPS Growth 3Y | 9.41% | Sales Growth 3Y | 14.82% |
Fagron is a pharmaceutical compounding company that delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients. Operating through Essentials, Brands, and Compounding Services segments, it offers products such as DiluCap and DiluTab excipients, the Pentravan and SyrSpend SF delivery systems, and dermatological and hair care lines including Fagron Advanced Derma and TrichoConcept, as well as professional education through the Fagron Academy. Formerly Arseus, it took the Fagron name in January 2015. Founded in 1990, the company is based in Nazareth, Belgium.
| Market Cap | $1.94B | Trading Days | 4186 |
| 52W High | 25.30 |
| 52W Low | 19.24 |
| % Off High | −7.91% |
| YTD | 9.39% | 1Y | 4.25% |
| 3Y | 49.05% | 5Y | 43.57% |
| 10Y | 258.83% | Since incept. (ann.) | 8.76% |
| Ann. Volatility (1Y) | 20.50% | Ann. Volatility (3Y) | 20.50% |
| Sharpe (1Y) | 0.31 | Sharpe (3Y) | 0.78 |
| Max Drawdown (1Y) | −13.55% | Max Drawdown (3Y) | −16.46% |
| Beta (3Y, vs SPY) | 0.48 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| PGEN | PRECIGEN, INC. | $1.94B | — |
| FTRE | Fortrea Holdings Inc. | $1.94B | — |
| AUPH | Aurinia Pharmaceuticals Inc. | $1.95B | 7.3 |
| SNDA | SONIDA SENIOR LIVING, INC. | $1.93B | — |
| RAPP | Rapport Therapeutics, Inc. | $1.96B | — |
| ZBIO | Zenas BioPharma, Inc. | $1.96B | — |
| URGN | UroGen Pharma Ltd. | $1.97B | — |
| UFPT | UFP TECHNOLOGIES INC | $1.97B | 29.2 |
| WGS | GeneDx Holdings Corp. | $1.89B | — |
| ANIP | ANI PHARMACEUTICALS INC | $2.00B | 24.6 |
| SLS | SELLAS Life Sciences Group, Inc. | $1.88B | — |
| ADMA | ADMA BIOLOGICS, INC. | $2.02B | 14.5 |
